Consolidated Investment Analysis for YM BioSciences Inc. YM BioSciences Inc (AMEX:YMI) Company Description YM BioSciences Inc (AMEX:YMI) a biopharmaceutical company, engages in the licensing and commercialization of drug products and technologies primarily for the treatment of cancer or cancer-related conditions worldwide. Its approved product Nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor, is used for the treatment nasopharyngeal carcinomas, head and neck cancer, refractory children glioma, adult glioma, and stage III/IV glioma. The company is also developing Nimotuzumab for various other epithelial cancers; and AeroLEF, a proprietary formulation of free and liposome-encapsulated fentanyl administered by pulmonary inhalation for the treatment of severe and moderate acute pain, including cancer pain. In addition, its other product candidates include TGFa and HER-1, the anti-cancer vaccines. The company was formerly known as York Medical Inc. and changed its name to YM Biosciences Inc. in February 2001. YM Biosciences was founded in 1994 and is headquartered in Mississauga, Canada. Share Statistics Symbol
YMI
Beta
1.87
Current Price
$2.22
Market Capitalization:
176.98M
52 week range
$1.06 - $2.24
Outstanding Shares
80.39M
Avg Volume
1.07M
Shares Float
78.56M
Financial Summary YM BioSciences Inc (AMEX:YMI) has earned the revenue of $0.34 million for the quarter ended September 30th, 2010 whereas for the 12 months ended June 30 th, 2010 the company generated the total revenue of $2.61 million. The company’s total assets accumulate up to $51.11 million with highest proportion of current assets standing at $46.40 million. The company maintains the current ratio of 10.06 times which depicts that the company maintains current assets 10.06 times more than its current liabilities. The strong short term liquidity position of the company is also evident from the fact that its cash and cash equivalent of $40.17 million covers the current liabilities by 10 times.
Analysts’ Consensus
Buy
Overweight
Hold
Underweight
Sell
The consensus based on 4 analysts’ recommendation for YM BioSciences Inc (AMEX:YMI) is as follows:Analyst Detail
Buy
Overweight
Hold
Underweight
Sell
Current
3
0
1
0
0
One Month Ago
3
0
1
0
0
Months 2
0
1
0
0
Three Ago
Based on consensus of the recommendations of four analysts the share price for YMI falls in overweight on basis of median. However 3 out of 4 analysts recommend the buy for the share price. Technical Analysis Chart
Disclaimer:
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE OR IN ONE OF OUR NEWSLETTERS. We are not registered as a securities brokerdealer or an investment advisor either within the U.S. Securities and Exchange Commission (the “SEC�) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
The information contained on our website or in any of our newsletters should be viewed as commercial advertisement and is not intended to be investment advice. Any information found on our website, or in any of our newsletters is not provided to any particular individual with a view toward their individual circumstances. The information contained on our website, and in any newsletter we distribute, is not an offer to buy or sell securities. We distribute opinions, comments, and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained on our website or in one of our newsletters about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment adviser or licensed stock broker before investing.
This website is a service of Seo Freisin, Inc., a financial public relations firm that has been compensated by the companies profiled. All direct and third party compensation received has been disclosed on both, this newsletter, and on our website in accordance with section 17(b) of the Securities Act of 1933. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies.
Seo Freisin, Inc., and/or its affiliates will hold, buy, and sell securities in the companies profiled. When compensated in shares, all readers should be aware that it is our policy to liquidate all shares immediately. We reserve the right to buy or sell the shares of any the companies mentioned in any materials we produce at any time. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies.
Information contained in our report will contain “forward looking statements” as defined under section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.
We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance asto the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.
To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in this report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).